Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Personalis ,...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK , July 21, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars...
Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in minimal residual disease (MRD)...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...
MILWAUKEE , July 20, 2026 /PRNewswire/ -- Ademi LLP is investigating Personalis (NASDAQ: PSNL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth ...
Regulatory milestone for the NeXT Personal® Dx test enables clinical use of Personalis’ ultrasensitive MRD detection in Great Britain
Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs